214
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Effect of NLRP3 repression on NLRP3 inflammasome activation in human corneal epithelial cells with black carbon exposure

, , , , &
Pages 107-112 | Received 26 Oct 2021, Accepted 22 Feb 2022, Published online: 17 Mar 2022

References

  • Brauer M, Amann M, Burnett RT, et al. Exposure assessment for estimation of the global burden of disease attributable to outdoor air pollution. Environ Sci Technol 2012;46:652–660.
  • Hong J, Zhong T, Li H, et al. Ambient air pollution, weather changes, and outpatient visits for allergic conjunctivitis: a retrospective registry study. Sci Rep 2016;6:23858.
  • Tang YJ, Chang HH, Chiang CY, et al. A murine model of acute allergic conjunctivitis induced by continuous exposure to particulate matter 2.5. Invest Ophthalmol Vis Sci 2019;60:2118–2126.
  • Mo Z, Fu Q, Lyu D, et al. Impacts of air pollution on dry eye disease among residents in Hangzhou, China: a case-crossover study. Environ Pollut 2019;246:183–189.
  • Ni M, Huang J, Lu S, et al. A review on black carbon emissions, worldwide and in China. Chemosphere 2014;107:83–93.
  • Niranjan R, Thakur AK. The toxicological mechanisms of environmental soot (black carbon) and carbon black: focus on oxidative stress and inflammatory pathways. Front Immunol 2017;8:763.
  • Guilbert A, De Cremer K, Heene B, et al. Personal exposure to traffic-related air pollutants and relationships with respiratory symptoms and oxidative stress: a pilot cross-sectional study among urban green space workers. Sci Total Environ 2019;649:620–628.
  • Chu H, Hao W, Cheng Z, et al. Black carbon particles and ozone-oxidized black carbon particles induced lung damage in mice through an interleukin-33 dependent pathway. Sci Total Environ 2018;644:217–228.
  • Li Y, Ouyang Y, Jiao J, et al. Exposure to environmental black carbon exacerbates nasal epithelial inflammation via the reactive oxygen species (ROS)-nucleotide-binding, oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3)-caspase-1-interleukin 1β (IL-1β) pathway. Int Forum Allergy Rhinol 2021;11:773–783.
  • Kelley N, Jeltema D, Duan Y, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. IJMS 2019;20:6.
  • Fusco R, Siracusa R, Genovese T, et al. Focus on the role of NLRP3 inflammasome in diseases. IJMS 2020;21:4223.
  • Marchetti C. The NLRP3 inflammasome as a pharmacological target. J Cardiovasc Pharmacol 2019;74:285–296.
  • Long Q, Wang L, Shang J, et al. Black carbon induces complement activation via NLRP3 inflammasome in human corneal epithelial cells. Current Eye Research 2021:1–6.
  • Long Q, Huang Y, Shang J, et al. Black carbon induces cytotoxicity and NLRP3 inflammasome activation in human corneal epithelial cells. Current Eye Research 2020;45:680–685.
  • Zheng Q, Ren Y, Reinach PS, et al. Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients. Exp Eye Res 2015;134:133–140.
  • Xing JH, Li R, Gao YQ, et al. NLRP3 inflammasome mediate palmitate-induced endothelial dysfunction. Life Sci 2019;239:116882.
  • Chu H, Shang J, Jin M, et al. Comparison of lung damage in mice exposed to black carbon particles and ozone-oxidized black carbon particles. Sci Total Environ 2016;573:303–312.
  • Nwanaji-Enwerem JC, Wang W, Nwanaji-Enwerem O, et al. Association of long-term ambient black carbon exposure and oxidative stress allelic variants with intraocular pressure in older men. JAMA Ophthalmol 2019;137:129–137.
  • Almetwally AA, Bin-Jumah M, Allam AA. Ambient air pollution and its influence on human health and welfare: an overview. Environ Sci Pollut Res Int 2020;27:24815–24830.
  • Zahid A, Li B, Kombe AJK, et al. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol 2019;10:2538.
  • Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 2019;10:128.
  • Kuwar R, Rolfe A, Di L, et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation 2019;16:81.
  • Nikam RR, Gore KR. Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther 2018;28:209–224.
  • Crooke ST, Witztum JL, Bennett CF, et al. RNA-targeted therapeutics. Cell Metab 2018;27:714–739.
  • Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev 2015;265:6–21.
  • Mathur A, Hayward JA, Man SM. Molecular mechanisms of inflammasome signaling. J Leukoc Biol 2018;103:233–257.
  • Zhang H, Zahid A, Ismail H, et al. An overview of disease models for NLRP3 inflammasome over-activation. Expert Opin Drug Discov 2021;16:429–446.
  • Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 2013;25:389–393.
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev 2011;22:189–195.
  • Sollberger G, Strittmatter GE, Garstkiewicz M, et al. Caspase-1: the inflammasome and beyond. Innate Immun 2014;20:115–125.
  • Greenbaum D, Colangelo C, Williams K, et al. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003;4:117.
  • de Sousa Abreu R, Penalva LO, Marcotte EM, et al. Global signatures of protein and mRNA expression levels. Mol Biosyst 2009;5:1512–1526.
  • Ghasemi H. Roles of IL-6 in ocular inflammation: a review. Ocul Immunol Inflamm 2018;26:37–50.
  • Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010;3:cm1.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.